Effects of Chromium Brewer’s Yeast Supplementation on Body Mass, Blood Carbohydrates, and Lipids and Minerals in Type 2 Diabetic Patients

Abstract

Chromium(III) is considered as an essential element for carbohydrate and lipid metabolism. The aim of this clinical study was to evaluate the efficacy of Cr brewer’s yeast supplementation on body mass, carbohydrate, lipids and mineral indices in type 2 diabetic patients. Twenty adult type 2 diabetic subjects (11 males and 9 females aged 37–63) were supplemented with Cr brewer’s yeast in dosages of 500 μg Cr/person/day or placebo for 8 weeks in a double-blind, placebo-controlled crossover design. It was found that supplemental Cr did not affect body mass, blood lipid profile, resistin levels, and the serum and hair Zn, Fe, and Cu levels, but increased serum Cr (by 116%) and hair Cr (by 20.6%) concentrations and improved some blood carbohydrate indices (significant increase in the β cell function index by 18.8%) in type 2 diabetic patients. In conclusion, Cr brewer’s yeast has a weak hypoglycemic potential, but does not affect body mass, blood biochemical profile, and microelement levels in type 2 diabetic subjects.

This is a preview of subscription content, access via your institution.

Scheme 1

References

  1. 1.

    Stallings D, Vincent JB (2006) Chromium. A case study in how not to perform nutritional research. Curr Topics Nutraceut Res 4:89–112

    CAS  Google Scholar 

  2. 2.

    Davis CM, Vincent JB (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36:4382–4385

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Davis CM, Sumrall KH, Vincent JB (1996) A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry 35:12963–12969

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Vincent JB (2000) Elucidating a biological role for chromium at a molecular level. Acc Chem Res 37:503–510

    Article  Google Scholar 

  5. 5.

    Penumathsa SV, Thirunavukkarasu M, Samuel SM et al (2009) Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim Biophys Acta 1792:39–48

    PubMed  CAS  Google Scholar 

  6. 6.

    Davies S, Howard JM, Hinnisett A et al (1997) Age-related decreases in chromium levels in 51, 665 hair, sweat, and serum samples from 40,872 patients: implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 46:469–473

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Morris BW, MacNeil S, Hardisty CA (1999) Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol 13:57–61

    PubMed  CAS  Google Scholar 

  8. 8.

    Kazi TG, Afridi HI, Kazi N et al (2008) Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res 122:1–18

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Rajpathak S, Rimm EB, Li T et al (2004) Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diab Care 27:2211–2216

    Article  CAS  Google Scholar 

  10. 10.

    Stupar J, Vrtovec M, Dolinek F (2007) Longitudial hair chromium profiles of eldery subjects with normal glucose tolerance and type 2 diabetes mellitus. Metab Clin Exp 56:94–104

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Jeejeebhoy KN, Chu RC, Marliss EB et al (1977) Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 30:531–538

    PubMed  CAS  Google Scholar 

  12. 12.

    (2001) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, jodinc, iron, manganese, molybdenum, nickel, silicon, vanadium: chromium. National Academy Press, Washington, DC, pp 197–223

  13. 13.

    Anderson RA, Cheng N, Bryden NA et al (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786–1791

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Cefalu WT, Bell-Farrow AD, Stegner J et al (1999) Effect of chromium picolinate in insulin sensitivity in vivo. J Trace Elem Exp Med 12:71–83

    Article  CAS  Google Scholar 

  15. 15.

    Bahijiri SM, Mira SA, Mufti AM et al (2000) The effect of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J 21:831–837

    PubMed  CAS  Google Scholar 

  16. 16.

    Anderson RA, Roussel A-M, Zouari N et al (2001) Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 20:212–218

    PubMed  CAS  Google Scholar 

  17. 17.

    Gosh D, Bhattacharyaa B, Mukherjeeb B et al (2002) Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 3:690–697

    Article  Google Scholar 

  18. 18.

    Martin J, Zhang XH, Zhong Q et al (2006) Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diab Care 29:1826–1832

    Article  CAS  Google Scholar 

  19. 19.

    Pei D, Hsieh CH, Hung YJ et al (2006) The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism 55:923–927

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Racek J, Trefil L, Rajdl D et al (2006) Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res 109:215–230

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Albarracin C, Fuqua B, Evans JL et al (2008) Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 24:41–51

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Anton SD, Morrison CD, Cefalu WT et al (2008) Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther 10:405–412

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Sacks DB, Bruns DE, Goldstein DE et al (2002) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48:436–472

    PubMed  CAS  Google Scholar 

  24. 24.

    Shephard MD, Whiting MJ (1990) Falsely low estimation of triglycerides in lipemic plasma by the enzymatic triglyceride method with modified Trinder’s chromogen. Clin Chem 36:325–329

    PubMed  CAS  Google Scholar 

  25. 25.

    Riesen WF (1998) Lipid metabolism. In: Thomas L (ed) Clinical laboratory diagnostics. Use and assessment of clinical laboratory results. TH-Books Verlagssesellschaft, Frankfurt (Main), pp 167–169

    Google Scholar 

  26. 26.

    Miki Y (1999) A homogenous assay for the selective measurement of LDL-cholesterol in serum. Enzymatic selective protection method. Clin Lab 45:398–401

    Google Scholar 

  27. 27.

    Berg AH, Sacks DB (2008) Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony. J Clin Pathol 61:983–987

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Monti LD, Sandoli EP, Phan VC et al (1995) A sensitive and reliable method for assaying true human insulin without interaction with human proinsulin-like molecules. Acta Diabetol 32:57–63

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    International Atomic Energy Agency Reports 1984, 1985, 1987, Vienna, Coordinated research programme on the significance of hair metal analysis as a means for assessing internal body burdens of environmental exposure

  31. 31.

    Gunton JE, Cheung NW, Hitchman R et al (2005) Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile. Diab Care 28:712–714

    Article  Google Scholar 

  32. 32.

    Iqbal N, Cardillo S, Volger S et al (2009) Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord 7:143–150

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Kleefstra N, Houweling S, Jansman FGA et al (2006) Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population. Diab Care 29:321–325

    Article  Google Scholar 

  34. 34.

    American Diabetes Association (2008) A position statement of the American Diabetes Association. Nutrition recommendations and ınterventions for diabetes. Diabetes Care 31:61–78

    Article  Google Scholar 

  35. 35.

    Mann JI, De Leeuw I, Hermansen K, Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) et al (2004) Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 14:373–394

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Balk EM, Tatsioni A, Lichtenstein AH et al (2007) Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diab Care 30:2154–2163

    Article  CAS  Google Scholar 

  37. 37.

    Lai MH (2008) Antioxidant effects and insulin resistance improvement of chromium combined with vitamin C and supplementation for type 2 diabetes mellitus. J Clin Biochem Nutr 43:191–198

    PubMed  Article  Google Scholar 

  38. 38.

    Wang ZQ, Qin J, Martin J et al (2007) Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metab Clin Exp 56:1652–1655

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Pattar GR, Tackett L, Liu P et al (2006) Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 610:93–100

    PubMed  CAS  Google Scholar 

  40. 40.

    Chen G, Liu P, Pattar GR (2006) Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 20:857–870

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Osawa H, Ochi M, Tabara Y et al (2008) Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 69:74–80

    Article  CAS  Google Scholar 

  42. 42.

    Chen BH, Song Y, Ding EL (2009) Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diab Care 32:329–334

    Article  CAS  Google Scholar 

  43. 43.

    Wang YQ, Dong Y, Yao MH (2009) Chromium picolinate inhibits resistin secretion in insulin-resistant 3T3-L1 adipocytes via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol 36:843–849

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Clodfelder BJ, Emamaullee J, Hepburn DD et al (2001) The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin. J Biol Inorg Chem 6:608–617

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Lukaski HC, Siders WA, Penland JG (2007) Chromium picolinate supplementation in women: effect on body weight, composition and iron status. Nutrition 23:187–195

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Campbell WW, Joseph LJ, Davey SL (1999) Effects of resistance training and chromium picolinate on body composition and skeletal muscle in older men. J Appl Physiol 86:29–39

    PubMed  CAS  Google Scholar 

  47. 47.

    Campbell WW, Joseph LJ, Anderson RA (2002) Effects of resistive training and chromium picolinate on body composition and skeletal muscle size in older women. Int J Sport Nutr Exerc Metab 12:125–135

    PubMed  CAS  Google Scholar 

  48. 48.

    Volpe SL, Huang HW, Larpadisorn K (2001) Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr 20:293–306

    PubMed  CAS  Google Scholar 

  49. 49.

    Dogukan A, Sahin N, Tuzcu M et al (2009) The effects of chromium histidinate on mineral status of serum and tissue in fat-fed and streptozotocin-treated type II diabetic rats. Biol Trace Elem Res 131:124–132

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of Interest Statement

The authors declare that they have no conflicts of interest.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Zbigniew Krejpcio.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Król, E., Krejpcio, Z., Byks, H. et al. Effects of Chromium Brewer’s Yeast Supplementation on Body Mass, Blood Carbohydrates, and Lipids and Minerals in Type 2 Diabetic Patients. Biol Trace Elem Res 143, 726–737 (2011). https://doi.org/10.1007/s12011-010-8917-5

Download citation

Keywords

  • Chromium(III) brewer’s yeast
  • Supplementation
  • Diabetes type 2